Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 11, Novembre 2002
Page(s) 1049 - 1051
Section Le Magazine : Nouvelles
DOI https://doi.org/10.1051/medsci/200218111049
Publié en ligne 15 novembre 2002
  1. Writing Group for the Women’s Health Initiative Investigator. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288 : 321–33.
  2. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288 : 334–41.
  3. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293–7.
  4. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332 : 1589–93.
  5. Collaborative Group on Hormonal factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350 : 1047–1059.
  6. Shairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999; 91 : 264–70.
  7. Bonnier P, Sakr R, Bennessay F, et al. Effects of hormone replacement therapy for menopause on prognostic factors of breast cancer. Gynecol Obstet Fertil 2000; 28 : 745–53.
  8. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001; 86 : 16–23.
  9. Hulley S, Furberg C, Barrett-Connor E, et al. for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study followup (HERS II). JAMA 2002; 288 : 58–66.
  10. Expertise Collective Inserm. Hormone replacement therapy. Influence on cardiovascular risk. Paris : Éditions Inserm, 2000.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.